NYSE:DPLO - Diplomat Pharmacy Stock Price, Forecast & News

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.35) EPS for the quarter, missing the consensus estimate of ($0.20) by $2.15. The business had revenue of $1.30 billion for the quarter, compared to analysts' expectations of $1.17 billion. Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. Diplomat Pharmacy's revenue was down 5.3% compared to the same quarter last year. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of $-4.91--4.81 for the period, compared to the Thomson Reuters consensus EPS estimate of $-2.67. The company issued revenue guidance of $$4.9-5.1 billion, compared to the consensus revenue estimate of $$4.87 billion.

12 equities research analysts have issued 12 month price targets for Diplomat Pharmacy's shares. Their forecasts range from $3.00 to $30.00. On average, they anticipate Diplomat Pharmacy's share price to reach $8.00 in the next year. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings and 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Headlines about DPLO stock have been trending negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Diplomat Pharmacy.

Diplomat Pharmacy saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,980,000 shares, a decline of 30.5% from the January 15th total of 4,290,000 shares. Based on an average daily trading volume, of 2,210,000 shares, the short-interest ratio is presently 1.3 days. Currently, 5.2% of the shares of the company are short sold. View Diplomat Pharmacy's Current Options Chain.

Some companies that are related to Diplomat Pharmacy include Rite Aid (RAD), Petmed Express (PETS), 111 (YI), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Ford Motor (F), Cara Therapeutics (CARA), CVS Health (CVS), General Motors (GM), Activision Blizzard (ATVI), Exelixis (EXEL) and Horizon Therapeutics (HZNP).

Diplomat Pharmacy's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.36%), State Street Corp (2.69%), Charles Schwab Investment Management Inc. (1.83%), Water Island Capital LLC (0.93%), Bank of New York Mellon Corp (0.86%) and Gabelli Funds LLC (0.76%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Cambridge Investment Research Advisors Inc., Citigroup Inc., Arizona State Retirement System, Prudential Financial Inc., New York State Common Retirement Fund, Public Sector Pension Investment Board and State of Tennessee Treasury Department. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Regina M Benjamin. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Water Island Capital LLC, Gabelli Funds LLC, Dupont Capital Management Corp, Barclays PLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc. and SG Americas Securities LLC. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $4.00.

Diplomat Pharmacy has a market capitalization of $304 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]